The combination of VEGFR2 inhibitors and PD-1 inhibitors has been shown to induce vascular normalization in HCC, reducing vascular leakage, improving tumor perfusion, and thereby promoting immune cell infiltration into tumor tissues [151]. The gene discussed is KDR; the disease is hepatocellular carcinoma.